scholarly journals In vitro assay and in vivo effect of artemisinin in Trypanosoma brucei brucei-infected Wistar rats

2021 ◽  
Vol 1 (3) ◽  
pp. 100061
Author(s):  
Kelvin Olutimilehin Jolayemi ◽  
Mohammed Mamman ◽  
Dahiru Sani ◽  
Magdalene Ogbonneya Okoronkwo ◽  
Abubakar Usman ◽  
...  
Keyword(s):  
Trypanosoma Brucei ◽  
Wistar Rats ◽  
In Vitro Assay ◽  
Trypanosoma Brucei Brucei ◽  
Vitro Assay

scholarly journals Isothiochromenothiazoles—A Class of Fused Thiazolidinone Derivatives with Established Anticancer Activity That Inhibits Growth of Trypanosoma brucei brucei

2018 ◽  
Vol 86 (4) ◽  
pp. 47 ◽  
Author(s):  
Anna Kryshchyshyn ◽  
Danylo Kaminskyy ◽  
Igor Nektegayev ◽  
Philippe Grellier ◽  
Roman Lesyk
Keyword(s):  
Acute Toxicity ◽  
Anticancer Activity ◽  
Trypanosoma Brucei ◽  
In Vitro Assay ◽  
Parasite Growth ◽  
Trypanosoma Brucei Brucei ◽  
Vitro Assay ◽  
Antiparasitic Agents ◽  
Micromolar Range

Recently, thiazolidinone derivatives have been widely studied as antiparasitic agents. Previous investigations showed that fused 4-thiazolidinone derivatives (especially thiopyranothiazoles) retain pharmacological activity of their synthetic precursors—simple 5-ene-4-thiazolidinones. A series of isothiochromeno[4a,4-d][1,3] thiazoles was investigated in an in vitro assay towards bloodstream forms of Trypanosoma brucei brucei. All compounds inhibited parasite growth at concentrations in the micromolar range. The established low acute toxicity of this class of compounds along with a good trypanocidal profile indicates that isothiochromenothiazole derivatives may be promising for designing new antitrypanosomal drugs.

scholarly journals Effect of Massoia (Massoia aromatica Becc.) Bark on the Phagocytic Activity of Wistar Rat Macrophages

2018 ◽  
Author(s):  
Triana Hertiani ◽  
Agustinus Yuswanto ◽  
Sylvia Utami Tunjung Pratiwi ◽  
Harlyanti Mashar
Keyword(s):  
Phagocytic Activity ◽  
Wistar Rats ◽  
In Vitro Assay ◽  
Phagocytic Index ◽  
Dependent Manner ◽  
Vitro Assay ◽  
Macrophage Cells ◽  
In Vivo Assay

Massoia (Massoia aromatica Becc., Lauraceae) bark has been widely used as a component of traditional Indonesian medicine. The indigenous people boil or steam the bark for traditional applications. Our preliminary research revealed the potency of Massoia essential oil and its major compound, C-10 Massoialactone as potential immunomodulator in vitro. However, no scientific evidence regarding its in vivo effects is available. Therefore, this study evaluated the potential immunomodulatory effects of Massoia bark infusion on the nonspecific immune response (phagocytosis) of Wistar rats. The aqueous extract of Massoia bark was obtained by boiling pulverized bark in water, and the C-10 massoialactone content of the extract was determined through Thin Layer Chromatography (TLC) densitometry. For the in vitro assay, macrophages were treated with the freeze-dried infusion at the concentrations of 2.5, 5, 10, 20, or 40 μg/mL media. For the in vivo assay, 2-month-old male Wistar rats were divided into 5 groups. The baseline group received distilled water at the dose of 1 mL/100 g BW with the immunostimulant herbal product “X” administered as the positive control at the dose of 0.54 mL/rat. The treatment groups received the infusion at a dose of 100, 300, or 500 mg/100 g BW. Treatments were given orally every day for 14 days. The ability of macrophage cells to phagocyte latex was determined as phagocytic index (PI) and was observed under microscopy with 300 macrophages. The in vitro study revealed that the phagocytic activity of the infusion-treated macrophages significantly increased in comparison with that of the control macrophages in a concentration-dependent manner. Among all treatment concentrations, the concentration of 40 μg/ml provided the highest activity with a PI value of 70.51% ± 1.11%. The results of the in vivo assay confirmed those of the in vitro assay. The results of the present study indicate that Massoia bark can increase the phagocytic activity of rat macrophage cells. Its potential as a naturally derived immunomodulatory agent requires further study.

scholarly journals In vitro and in vivo changes observed in Trypanosoma brucei brucei-infected rats treated with artesunate and/or diminazene aceturate

2021 ◽  
Vol 18 (4) ◽  
pp. 211-220 ◽  
Author(s):  
KO Jolayemi ◽  
M. Mamman ◽  
D. Sani ◽  
M.O. Okoronkwo ◽  
J. Amaje
Keyword(s):  
Trypanosoma Brucei ◽  
Wistar Rats ◽  
Standard Dose ◽  
Total Leucocyte Count ◽  
Post Inoculation ◽  
Trypanosoma Brucei Brucei ◽  
Diminazene Aceturate ◽  
Model Control

This study evaluated in vitro and in vivo antitrypanosomal effect of artesunate and/or diminazene aceturate in Wistar rats experimentally  infected with Trypanosoma brucei brucei. In vitro screening was carried out in triplicates using 50 μl of 0.2, 2 and 20 μg/μl of artesunate as test drug; diminazene aceturate, normal saline and trypanosome-infected blood served as controls in a 96-well microtitre plate, incubated at 37˚C for 5 minutes. Efficacy was observed over a period of 60 minutes for reduced or complete trypanosomal immobilization. Results showed concentration-dependent cessation of trypanosomal motility was significantly (p < 0.001) induced by artesunate when compared to the controls. Seventy Wistar rats of both sexes weighing between 190 and 210 g were randomly divided into 7 groups (5 males and 5 females) are used for in vivo study. Groups I and II served as normal control and model control respectively. Groups III to VII were infected with Trypanosoma brucei brucei (106 trypanosomes/ml) intraperitoneally. At peak parasitaemia (8 days post-infection), group III was treated with diminazene aceturate (3.5 mg/kg) intramuscularly once while groups IV, V, VI were treated with artesunate (200, 100, 50) mg/kg orally for 5 consecutive days and group VII was treated with combination of artesunate (50 mg/kg) orally and diminazene aceturate (1.75 mg/kg) intramuscularly for 5 days. Results indicated pre-patent period of 4 days and increase in levels of parasitaemia post-inoculation. PCV, Hb concentration, RBC count, MCV, MCHC and total leucocyte count decreased significantly (p < 0.05) between days 0and 8 in groups II to VII. Following treatment, significant increases (p < 0.05) were recorded except for groups II, IV, V and VI where the rats died. Thus, combination of artesunate (50 mg/kg) and half the standard dose of diminazene aceturate was able to reduce parasitaemia and ameliorate the anaemia elicited by the trypanosomes. Keywords: Artesunate, Diminazene Aceturate, Haematology, Trypanosoma brucei brucei, Wistar rats

scholarly journals DIGESTIBLE ENERGY IN FORAGE BYIN VIVOANDIN VITROASSAYS

1970 ◽  
Vol 50 (3) ◽  
pp. 557-562 ◽  
Author(s):  
J. E. TROELSEN
Keyword(s):  
Energy Analysis ◽  
Energy Content ◽  
In Vitro Assay ◽  
Pure Species ◽  
Vitro Assay ◽  
Digestible Energy ◽  
The Relationship ◽  
Cattle And Sheep

Forage of six pure species was harvested for hay at several maturity stages during four years. The digestible energy content of 102 different lots of hay was determined by feeding to four groups of sheep during the same period, and by in vitro digestions and energy analysis of the undigested residues. The relationship between digestible energy content assayed by the two methods was highly significant (r = 0.85) and did not differ between years and species. Exclusion from regression of the hays containing less than 2 or more than 3 digestible kcal/g revealed that the in vitro assay could reproduce the in vivo digestible energy value with a standard deviation of 0.31 in over 70% of the hays. This represented the maturity and quality range of forage commonly fed to cattle and sheep. The in vitro assay therefore appeared promising for commercial quality determinations.

scholarly journals Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis

2010 ◽  
Vol 54 (7) ◽  
pp. 2893-2900 ◽  
Author(s):  
Antoaneta Y. Sokolova ◽  
Susan Wyllie ◽  
Stephen Patterson ◽  
Sandra L. Oza ◽  
Kevin D. Read ◽  
...  
Keyword(s):  
Trypanosoma Brucei ◽  
Human African Trypanosomiasis ◽  
Parent Drug ◽  
Cross Resistance ◽  
Pharmacokinetic Studies ◽  
African Trypanosomiasis ◽  
Trypanosoma Brucei Brucei ◽  
Resistant Lines

ABSTRACT The success of nifurtimox-eflornithine combination therapy (NECT) for the treatment of human African trypanosomiasis (HAT) has renewed interest in the potential of nitro drugs as chemotherapeutics. In order to study the implications of the more widespread use of nitro drugs against these parasites, we examined the in vivo and in vitro resistance potentials of nifurtimox and fexinidazole and its metabolites. Following selection in vitro by exposure to increasing concentrations of nifurtimox, Trypanosoma brucei brucei nifurtimox-resistant clones designated NfxR1 and NfxR2 were generated. Both cell lines were found to be 8-fold less sensitive to nifurtimox than parental cells and demonstrated cross-resistance to a number of other nitro drugs, most notably the clinical trial candidate fexinidazole (∼27-fold more resistant than parental cells). Studies of mice confirmed that the generation of nifurtimox resistance in these parasites did not compromise virulence, and NfxR1 remained resistant to both nifurtimox and fexinidazole in vivo. In the case of fexinidazole, drug metabolism and pharmacokinetic studies indicate that the parent drug is rapidly metabolized to the sulfoxide and sulfone form of this compound. These metabolites retained trypanocidal activity but were less effective in nifurtimox-resistant lines. Significantly, trypanosomes selected for resistance to fexinidazole were 10-fold more resistant to nifurtimox than parental cells. This reciprocal cross-resistance has important implications for the therapeutic use of nifurtimox in a clinical setting and highlights a potential danger in the use of fexinidazole as a monotherapy.

scholarly journals Mutagenicity evaluation of Anastatica hierochuntica L. aqueous extract in vitro and in vivo

2017 ◽  
Vol 243 (4) ◽  
pp. 375-385 ◽  
Author(s):  
Siti Rosmani Md Zin ◽  
Zahurin Mohamed ◽  
Mohammed A Alshawsh ◽  
Won F Wong ◽  
Normadiah M Kassim
Keyword(s):  
Aqueous Extract ◽  
Positive Control ◽  
In Vitro Assay ◽  
In Vivo Study ◽  
Sufficient Evidence ◽  
Aqueous Extracts ◽  
Mutagenic Potential ◽  
Vitro Assay

Anastatica hierochuntica L. ( A. hierochuntica), a folk medicinal plant, was evaluated for mutagenic potential via in vitro and in vivo assays. The in vitro assay was conducted according to modified Ames test, while the in vivo study was performed according to Organisation for Economic Co-operation and Development guideline for mammalian erythrocyte micronucleus assay. Four groups ( n= 5 males and 5 females per group) Sprague Dawley rats were randomly chosen as the negative control, positive control (received a single intramuscular injection of cyclophosphamide 50 mg/kg), 1000 and, 2000 mg/kg A. hierochuntica aqueous extracts. All groups except the positive control were treated orally for three days. Findings of the in vitro assay showed mutagenic potential of AHAE at 0.04 and 0.2 mg/ml. However, no mutagenic effect was demonstrated in the in vivo study up to 2000 mg/kg. No significant reduction in the polychromatic and normochromatic erythrocytes ratio was noted in any of the groups. Meanwhile, high micronucleated polychromatic erythrocytes frequency was seen in cyclophosphamide-treated group only. These findings could perhaps be due to insufficient dosage of A. hierochuntica aqueous extracts to cause genetic damage on the bone marrow target cells. Further acute and chronic in vivo toxicity studies may be required to draw pertinent conclusion on the safety aspect of A. hierochuntica aqueous extracts consumption. Impact statement In this paper, we report on the mutagenicity evaluation of Anastatica hierochuntica aqueous extract. This is a significant research in view of the popularity of this herb consumption by the people across the globe despite of limited scientific evidence on its toxicity potential. This study is intended to encourage more extensive related research in order to provide sufficient evidence and guidance for determining its safe dosage.

Sign in / Sign up

Export Citation Format

Share Document